Zuragen Injection for CRBSI

September 16, 2008

Email this news item to a friend/colleague

Ash Access Technology, Inc. announced that the last patient enrolled in the AZEPTIC Trial for Zuragen(TM) Injection has completed the study. The AZEPTIC Trial was a randomized study evaluating the efficacy and safety of Zuragen(TM) Injection in reducing the incidence of catheter-related bloodstream infection (CRBSI) in patients requiring the use of a central venous catheter (CVCs) for hemodialysis. The trial enrolled over 400 patients at 25 dialysis facilities across the United States. Portions of the AZEPTIC Trial were financed through grants awarded by the National Institutes of Health (NIH) and the Indiana 21st Century Technology Fund.

Zuragen(TM) Injection is a non-antibiotic, antimicrobial / antithrombotic therapy that is administered into a patient’s catheter at the conclusion of each hemodialysis session. The product’s unique components have demonstrated a novel synergy which has led to significant and rapid efficacy against a broad spectrum of bacteria and fungus as well as complete elimination of biofilm in pre-clinical studies.

Click here for the full story on Marketwatch.